headquartered in redwood city, california, nevro is a global medical device company focused on providing innovative products that improve the quality of life of patients suffering from debilitating chronic pain. nevro has developed and commercialized the senza spinal cord stimulation (scs) system, an evidence-based neuromodulation platform for the treatment of chronic pain. the senza system is the only scs system that delivers nevro's proprietary hf10 therapy. the nevro® senza® scs system received ce mark in 2010, tga approval in 2011, fda approval in 2015, and is commercially available in europe, australia, and the united states.
Company profile
Ticker
NVRO
Exchange
Website
CEO
D.Keith Grossman
Employees
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
Subsidiaries
Nevro Medical Sarl • Nevro Medical Limited • Nevro Medical Pty Ltd. • Nevro Germany GmbH • Nevro Medical, S.R.L. ...
NVRO stock data
Latest filings (excl ownership)
DEFA14A
Additional proxy soliciting materials
12 Apr 24
DEF 14A
Definitive proxy
12 Apr 24
S-8
Registration of securities for employees
23 Feb 24
10-K
2023 FY
Annual report
23 Feb 24
8-K
Nevro Enters Into Cooperation Agreement With Engaged Capital
21 Feb 24
8-K
Nevro Reports Fourth-Quarter and Full-Year 2023 Financial Results
21 Feb 24
EFFECT
Notice of effectiveness
11 Jan 24
424B3
Prospectus supplement
10 Jan 24
8-K
Nevro Announces Preliminary Fourth-Quarter and Full-Year 2023 Revenue Results
9 Jan 24
CORRESP
Correspondence with SEC
8 Jan 24
Transcripts
NVRO
Earnings call transcript
2023 Q4
21 Feb 24
NVRO
Earnings call transcript
2023 Q3
1 Nov 23
NVRO
Earnings call transcript
2023 Q2
1 Aug 23
NVRO
Earnings call transcript
2023 Q1
26 Apr 23
NVRO
Earnings call transcript
2022 Q4
16 Feb 23
NVRO
Earnings call transcript
2022 Q3
3 Nov 22
NVRO
Earnings call transcript
2022 Q2
7 Aug 22
NVRO
Earnings call transcript
2022 Q1
7 May 22
NVRO
Earnings call transcript
2021 Q4
24 Feb 22
NVRO
Earnings call transcript
2021 Q3
9 Nov 21
Latest ownership filings
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 65.16 mm | 65.16 mm | 65.16 mm | 65.16 mm | 65.16 mm | 65.16 mm |
Cash burn (monthly) | 10.33 k | 5.47 mm | 8.52 mm | 8.91 mm | 2.03 mm | 5.28 mm |
Cash used (since last report) | 68.84 k | 36.47 mm | 56.76 mm | 59.34 mm | 13.52 mm | 35.16 mm |
Cash remaining | 65.09 mm | 28.69 mm | 8.40 mm | 5.82 mm | 51.63 mm | 30.00 mm |
Runway (months of cash) | 6298.7 | 5.2 | 1.0 | 0.7 | 25.4 | 5.7 |
Institutional ownership, Q3 2023
13F holders | Current |
---|---|
Total holders | 138 |
Opened positions | 12 |
Closed positions | 32 |
Increased positions | 73 |
Reduced positions | 37 |
13F shares | Current |
---|---|
Total value | 663.96 bn |
Total shares | 37.33 mm |
Total puts | 308.50 k |
Total calls | 125.50 k |
Total put/call ratio | 2.5 |
Largest owners | Shares | Value |
---|---|---|
Vanguard | 4.23 mm | $81.34 bn |
Armistice Capital | 3.46 mm | $66.42 bn |
BLK Blackrock | 3.13 mm | $60.16 bn |
ArrowMark Colorado | 2.47 mm | $47.44 bn |
Braidwell | 1.78 mm | $34.14 bn |
Alger Associates | 1.24 mm | $151.45 mm |
Rock Springs Capital Management | 1.21 mm | $23.29 bn |
D. E. Shaw & Co. | 1.13 mm | $21.78 bn |
D. E. Shaw & Co | 1.10 mm | $190.32 mm |
FMR | 1.08 mm | $20.85 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
11 Apr 24 | Grossman D Keith | Common Stock | Payment of exercise | Dispose F | No | No | 13.12 | 3,986 | 52.30 k | 211,444 |
4 Apr 24 | Kashif Rashid | Common Stock | Payment of exercise | Dispose F | No | No | 13.21 | 479 | 6.33 k | 165,983 |
31 Mar 24 | Kosaraju Sridhar | Common Stock | Grant | Acquire A | No | No | 0 | 1,090 | 0.00 | 18,486 |
31 Mar 24 | Weatherman Elizabeth H | Common Stock | Grant | Acquire A | No | No | 0 | 1,372 | 0.00 | 55,780 |
31 Mar 24 | Fischer Frank M | Common Stock | Grant | Acquire A | No | No | 0 | 1,159 | 0.00 | 57,500 |
News
RBC Capital Maintains Sector Perform on Nevro, Lowers Price Target to $16
15 Apr 24
Mizuho Maintains Neutral on Nevro, Lowers Price Target to $16
11 Apr 24
Wells Fargo Maintains Equal-Weight on Nevro, Lowers Price Target to $14
8 Apr 24
Where Nevro Stands With Analysts
3 Apr 24
Citigroup Maintains Neutral on Nevro, Lowers Price Target to $16
3 Apr 24
Press releases
Nevro to Report First-Quarter 2024 Financial Results and Host Earnings Conference Call on May 7, 2024
17 Apr 24
Non-Opioid Revolution: Beacons of Hope in Opioid Crisis and a $50 Million Spin-Off
9 Apr 24
Nevro Announces Consensus Statement Supporting High-Frequency (10 kHz) Spinal Cord Stimulation Therapy for Refractory Painful Diabetic Neuropathy
1 Feb 24
Nevro to Report Fourth-Quarter and Full-Year 2023 Financial Results and Host Conference Call on February 21, 2024
29 Jan 24
Top 4 Spinal Injury Stocks for 2024 Watchlist (NRX.V, NVRO, SYK, BSX)
22 Jan 24